Phospholipidosis as a Function of Basicity, Lipophilicity, and Volume of Distribution of Compounds

被引:81
作者
Hanumegowda, Umesh M. [1 ]
Wenke, Gottfried [2 ]
Regueiro-Ren, Alicia [3 ]
Yordanova, Roumyana [4 ]
Corradi, John P. [4 ]
Adams, Stephen P. [1 ]
机构
[1] Bristol Myers Squibb Co, Res & Dev, Dept Discovery Toxicol, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Res & Dev, Dept Discovery Analyt Sci, Wallingford, CT 06492 USA
[3] Bristol Myers Squibb Co, Res & Dev, Dept Discovery Chem, Wallingford, CT 06492 USA
[4] Bristol Myers Squibb Co, Res & Dev, Dept Bioinformat, Wallingford, CT 06492 USA
关键词
DRUG-INDUCED PHOSPHOLIPIDOSIS; INDUCED GENERALIZED LIPIDOSIS; RAT-LIVER; ULTRASTRUCTURAL ALTERATIONS; PHARMACOKINETIC PARAMETERS; TRICYCLIC ANTIDEPRESSANTS; GENE-EXPRESSION; MYELOID BODIES; HEPG2; CELLS; GENTAMICIN;
D O I
10.1021/tx9003825
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug-induced phospholipidosis (PLD) is an adaptive histologic alteration that is seen with various marketed drugs and often encountered during drug development. Various in silico and in vitro cell-based methods have been developed to predict the PLD-inducing potential of compounds. These methods rely on the inherent physicochemical properties of the molecule and, as such, tend to overpredict compounds as PLD inducers. Recognizing that the distribution of compounds into tissues or tissue accumulation is likely a key factor in PLD induction, in addition to key physicochemical properties, we developed a model to predict PLD in vivo using the measures of basicity (pK(a)), lipophilicity (ClogP), and volume of distribution (V(d)). Using sets of PLD inducers and noninducers, we demonstrate improved concordance with this method. Furthermore, we propose a screening paradigm that includes a combination of various methods to predict the in vivo PLD-inducing potential of compounds, which may be especially useful in lead identification and optimization processes in drug discovery.
引用
收藏
页码:749 / 755
页数:7
相关论文
共 74 条
[11]   EARLY EFFECTS OF GENTAMICIN, TOBRAMYCIN, AND AMIKACIN ON THE HUMAN-KIDNEY [J].
DEBROE, ME ;
PAULUS, GJ ;
VERPOOTEN, GA ;
ROELS, F ;
BUYSSENS, N ;
WEDEEN, R ;
VANHOOF, F ;
TULKENS, PM .
KIDNEY INTERNATIONAL, 1984, 25 (04) :643-652
[12]   EXPERIMENTAL MYOPATHY INDUCED BY AMPHIPHILIC CATIONIC COMPOUNDS INCLUDING SEVERAL PSYCHOTROPIC-DRUGS [J].
DRENCKHAHN, D ;
LULLMANNRAUCH, R .
NEUROSCIENCE, 1979, 4 (04) :549-562
[13]   MUSCLE AND NERVE CHANGES INDUCED BY PERHEXILINE-MALEATE IN MAN AND MICE [J].
FARDEAU, M ;
TOME, FMS ;
SIMON, P .
MUSCLE & NERVE, 1979, 2 (01) :24-36
[14]  
FEDORKO ME, 1968, LAB INVEST, V18, P27
[15]  
GLAUMANN H, 1992, LIVER, V12, P183, DOI 10.1111/j.1600-0676.1992.tb01045.x
[16]   PENTAMIDINE ACCUMULATES IN RAT-LIVER LYSOSOMES AND INHIBITS PHOSPHOLIPID DEGRADATION [J].
GLAUMANN, H ;
BRONNER, U ;
ERICSSON, O ;
GUSTAFSSON, LL ;
ROMBO, L .
PHARMACOLOGY & TOXICOLOGY, 1994, 74 (01) :17-22
[17]   In silico human and rat Vss quantitative structure-activity relationship models [J].
Gleeson, MP ;
Waters, NJ ;
Paine, SW ;
Davis, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (06) :1953-1963
[18]   FLUOXETINE HYDROCHLORIDE (PROZAC)-INDUCED PULMONARY-DISEASE [J].
GONZALEZROTHI, RJ ;
ZANDER, DS ;
ROS, PR .
CHEST, 1995, 107 (06) :1763-1765
[19]  
GOODNICK PJ, 1991, PSYCHOPHARMACOL BULL, V27, P513
[20]   ULTRASTRUCTURAL STUDIES OF HEPATIC CHANGES BROUGHT ABOUT BY CLINDAMYCIN AND ERYTHROMYCIN IN ANIMALS [J].
GRAY, JE ;
PURMALIS, A ;
PURMALIS, B ;
MATHEWS, J .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1971, 19 (02) :217-&